MannKind & H&R Block Report: (NASDAQ:MNKD), (NYSE:HRB)
MannKind Corp. (NASDAQ:MNKD), a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.
View full press release